Questions discussed in this category
Have you changed your practice given BMT-CTN 1506/Morpho results?
Would you utilize maintenance therapy in patients who achieve MRD- remission?
How does graft source, conditioning regimen, and indication for transplant affect your decision regarding G-CSF?
Do you re-challenge them? If so, what pre-medications do you give? Do you dose reduce the cytarabine? Or do you switch another regimen?
If not, what instructions do you give to patients regarding checking temperature at home/return precautions?
It used to be a contraindication for G-CSF use for AML patients, but currently, several protocols include it to decrease neutropenic duration.
Does the absence of an OS benefit in the AG221-AML-005 presented at ASCO 2020 deter you from this strategy?
Would you consider “bridging” therapy with something like an HMA?
Does acute leukemia sub-type affect your decision?
Can it be added after 2 or 3 cycles of HMA?
1783618708129391524149421397312624106179951852183877251674175727372594440035196
Papers discussed in this category
Medical and pediatric oncology, 1981
Fertil. Steril., 2013 Sep 05
N. Engl. J. Med.,
Nature medicine, 2015-02
Clin Lymphoma Myeloma Leuk, 2017 Mar 07
Blood, 2013-05-02
Cochrane Database Syst Rev, 2012 Jun 13
N Engl J Med,
Blood, 2006 Sep 28
J Clin Oncol, 2010 Apr 20
J Clin Oncol,
Clin Infect Dis,
American journal of hematology, 2020 Dec 08
Blood cancer journal, 2023 Oct 11
Bone marrow transplantation, 2020 Dec 07
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2020 Jul 16
Archives of drug information, 2008-12
Bone marrow transplantation, 2003 Jul
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003 Dec 22
Leukemia, 2005 Apr
Transplantation and cellular therapy, 2021 Oct 02